⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
BMEA News
Biomea Fusion, Inc. Common Stock
Biomea Fusion Showcases Preclinical Advances for BMF-650 and Icovamenib with Low Dose Semaglutide at ObesityWeek® 2025
globenewswire.com
BMEA
Biomea Fusion Reports Third Quarter 2025 Financial Results and Corporate Highlights
globenewswire.com
BMEA
Biomea Fusion to Present Poster Presentations at ObesityWeek®2025
globenewswire.com
BMEA
Biomea Fusion Announces First Patient Dosed in Phase I Study of BMF-650 a Next-Generation Oral GLP-1 Receptor Agonist
globenewswire.com
BMEA
Biomea Fusion Announces Pricing of Public Offering of Securities
globenewswire.com
BMEA
Biomea Fusion Announces Proposed Public Offering of Securities
globenewswire.com
BMEA
Biomea Fusion Announces Positive 52-Week Results from Phase II COVALENT-111 Study in Type 2 Diabetes Demonstrating Non-Chronic Treatment with Icovamenib Benefits Two Distinct Patient Populations
globenewswire.com
BMEA
Biomea Fusion, Inc. Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4)
globenewswire.com
BMEA